Eltrombopag for Chemotherapy-induced Thrombocytopenia

Recruiting Phase 2 Interventional Study
Chemotherapy-induced Thrombocytopenia Eltrombopag
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
50 (estimated)
Sponsor
Institute of Hematology & Blood Diseases Hospital, China · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years old, male or female; * Conform to the diagnostic criteria of chemotherapy-induced thrombocytopenia (CIT); Ineffective after repeated treatment with rhTPO or IL-11; * Stop radiotherapy or chemotherapy for more than 1 month; * Platelet counts \<30 ×10\^9/L, and bl…
Contacts

Yunfei Chen, MD

+86-22-23909009

chenyunfei@ihcams.ac.cn

CONTACT

Lei Zhang, MD

+86-22-23909240

zhanglei1@ihcams.ac.cn

CONTACT